Group 1 - The core viewpoint of the article emphasizes the evolution of the "14th Five-Year Plan" reflecting timely updates in policy concepts, with a gradual softening of growth targets and a stronger focus on innovation, ecology, and security [1] - The document highlights the importance of "building a modern industrial system and consolidating the foundation of the real economy," placing it in a more prominent position in the narrative [1] - The term "new quality productivity" is introduced for the first time within the planning framework of the plenary session, indicating a shift in focus towards qualitative improvements in economic development [1] Group 2 - Economic development is increasingly prioritizing "qualitative effective enhancement and reasonable quantitative growth," integrating the principle of "combining effective markets with proactive government" into the overall strategy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6066） 海外監管公告 本 公 告 乃 中 信 建 投 証 券 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 之《中 信 建 投 証 券 股 份 有 限 公 司關於召開2025年 第 三 季 度 業 績 說 明 會 的 公 告》，僅 供 參 閱。 承董事會命 中信建投証券股份有限公司 董事長 劉 成 中國北京 2025年10月23日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 劉 成 先 生 及 金 劍 華 先 生；本 公 司 非 執 行 董 事 為 李 岷 先 生、朱 永 先 生、閆 小 雷 先 生、王 廣 龍 先 ...

证券代码：601066 证券简称：中信建投 公告编号：临 2025-056 号 中信建投证券股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 问题征集：股东及其他投资者可于 2025 年 10 月 28 日（星期二）至 11 月 3 日 （星期一）16:00 前，登录上证路演中心网站首页，点击"提问预征集"栏目或 通过公司邮箱（601066@csc.com.cn）进行提问。在信息披露允许的范围内，公 司将在说明会上对投资者普遍关注的问题进行回答。 中信建投证券股份有限公司（以下简称公司）将于 2025 年 10 月 30 日（星 期四）披露公司 2025 年第三季度报告，为便于广大投资者更加全面深入地了解 公司 2025 年前三季度经营情况，公司将于 2025 年 11 月 4 日（星期二）16:00-17:00 召开 2025 年第三季度业绩说明会，就投资者普遍关注的问题进行交流。 一、说明会类型 二、说明会召开的时间、地点 （一）召开时间：20 ...

Group 1 - The 2025 Sustainable Global Leaders Conference will be held from October 16 to 18 in Shanghai, focusing on building a new ecosystem for sustainable development in the securities industry through five key financial initiatives [1][2] - Key leaders from top Chinese securities firms, including China Galaxy Securities and CITIC Securities, will discuss the implementation of these five initiatives to support high-quality economic development in China [1] - The conference is co-hosted by the World Green Design Organization and Sina Group, with support from the Shanghai Huangpu District Government, aiming to explore new paths for sustainable development and inject "Chinese momentum" into global governance [1] Group 2 - The conference has upgraded from the previous four "ESG Global Leaders Conferences," inviting around 500 prominent guests, including approximately 100 international attendees, such as former political leaders, representatives from international organizations, Nobel Prize winners, and leaders from Fortune 500 companies [2]

Core Points - The stock of Huayu Pharmaceutical (688553.SH) closed at 21.28 yuan, reflecting a decline of 2.96% and is currently in a state of breaking below its initial public offering price [1] - Huayu Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, which was 453 million yuan more than the original plan [1] - The company intended to raise 1.907 billion yuan for projects including the construction of a second phase of the EU-standard injection production base and the establishment of an innovative drug research institute, as well as to supplement working capital [1] - The total issuance costs were 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities amounting to 98.875 million yuan [1]

Core Points - Huiyu Pharmaceutical (688553.SH) closed at 21.28 yuan, with a decline of 2.96%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering (IPO) of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] Fundraising and Financials - Huiyu Pharmaceutical raised a total of 2.472 billion yuan through the IPO, with a net amount of 2.361 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 453 million yuan [1] - The company intended to use the funds for the construction of the EU-standard injection production base (Phase II), the establishment of an innovative drug research institute, and to supplement working capital [1] - Total issuance costs amounted to 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities totaling 98.875 million yuan [1]

Core Points - Weijie Chuangxin (688153.SH) closed at 34.06 yuan, with a decline of 3.32%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 12, 2022, with an initial public offering (IPO) of 40.08 million shares at a price of 66.60 yuan per share [1] - The total amount raised from the IPO was 2.669 billion yuan, with a net amount of 2.502 billion yuan after deducting issuance costs, exceeding the original plan by 15.29 million yuan [1] - The funds raised are intended for integrated circuit production testing projects, research and development center construction projects, and to supplement working capital [1] - The total issuance costs for the IPO amounted to 166.82 million yuan, with underwriting and sponsorship fees accounting for 147.31 million yuan [1]

Core Points - The stock price of DiAo Micro (688381.SH) has decreased by 4.44%, closing at 25.84 yuan [1] - DiAo Micro was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 23, 2022, with an initial public offering (IPO) of 63.05 million shares at a price of 41.68 yuan per share [1][2] - The stock reached its highest price of 55.50 yuan on its first trading day but is currently in a state of decline [2] Fundraising and Financials - DiAo Micro raised a total of 262.79 million yuan from its IPO, with a net amount of 241.56 million yuan after deducting issuance costs, exceeding the original plan by 91.56 million yuan [2] - The company initially aimed to raise 150 million yuan for projects including the upgrade and industrialization of simulation chip products, the construction of a research and design center in Shanghai, a research and testing center in Nantong, and to supplement working capital [2] - The total issuance costs for the IPO amounted to 21.23 million yuan, with underwriting and sponsorship fees accounting for 18.08 million yuan [3]

Group 1 - The core point of the news is that Tongniu Information has seen a stock price increase of 5.23%, reaching 44.67 CNY per share, with a total market capitalization of 6.29 billion CNY [1] - Tongniu Information, established on September 21, 2005, and listed on September 24, 2020, is a comprehensive internet service provider based in Beijing, specializing in internet data center services, cloud services, internet access services, and application software development [1] - The revenue composition of Tongniu Information includes 66.76% from IDC and value-added services, 21.48% from other internet services, 10.00% from IDC and cloud platform system integration, and 1.76% from other supplementary services [1] Group 2 - Citic Securities Investment Fund has a significant holding in Tongniu Information, with the Citic Securities Zhenxuan Growth Mixed Fund A (018788) holding 17,000 shares, accounting for 3.44% of the fund's net value, making it the fourth-largest holding [2] - The Citic Securities Zhenxuan Growth Mixed Fund A was established on August 8, 2023, with a latest scale of 14.68 million CNY, achieving a year-to-date return of 20.24% [2] - The fund manager, Zhang Qing, has been in position for 4 years and 182 days, with the fund's total asset size at 22.83 million CNY, and the best and worst returns during his tenure being 21.35% and -20.83%, respectively [3]

Core Viewpoint - CITIC Securities maintains a "Buy" rating for Innovent Biologics (01801), projecting revenues of 11.806 billion yuan, 15.382 billion yuan, and 21.092 billion yuan for 2025-2027, respectively, with a DCF valuation indicating a fair market value of 221.5 billion HKD and a target price of 129.61 HKD [1] Group 1 - The company has established a significant presence in the oncology sector, with high-value clinical products expected to enhance revenue and reduce marginal costs [1] - In non-oncology sectors, the company has made extensive investments in metabolism, autoimmune diseases, and ophthalmology, with competitive and advanced products both launched and in development [1] Group 2 - On October 22, Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical, which will pay 1.2 billion USD upfront, including a strategic equity investment of 100 million USD at a subscription price of 112.56 HKD per share, representing a 20% premium over the weighted average share price of the past 30 trading days [1] - The total value of the collaboration could reach 11.4 billion USD, with Innovent Biologics and Takeda jointly developing IBI363 (PD-1/IL-2α-bias) [1] - Innovent Biologics granted Takeda exclusive rights for IBI343 (CLDN18.2ADC) outside Greater China and exclusive options for IBI3001 (EGFR/B7H3ADC) outside Greater China [1]